Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...

The wrestling icon announced in June that he would begin treatment for the issue following his second diagnosis in three ...

Neoadjuvant immunotherapy is associated with high rates of event-free survival in patients with resectable melanoma.

Castle Biosciences' DecisionDx-Melanoma test and Revolution Medicines' elironrasib cancer drug receive FDA Breakthrough ...

WWE Hall of Famer Ric Flair had to skip some recent public events due to health issues, which included receiving treatment ...

Ric Flair has provided a positive update on his health. The 16-time World Champion revealed in an interview with People last ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

WWE Hall of Famer Ric Flair is cancer free once again. Flair announced on Tuesday that he's completed his treatment for melanoma. Per TMZ, it was his second battle with skin cancer within the last ...

Replimune stock (ticker: REPL) cratered on Tuesday after the biotech said the U.S. Food and Drug Administration rejected an ...

The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license ...

We don’t know if skin cancer was the only health issue Ric Flair has been dealing with of late. Since being diagnosed with the most common form of cancer in the U.S. for the second time in three years ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...